Transcutaneous delivery of immunomodulating pollen extract-galactomannan conjugate by solid-in-oil nanodispersions for pollinosis immunotherapy

Qingliang Kong, Kouki Higasijima, Rie Wakabayashi, Yoshiro Tahara, Momoko Kitaoka, Hiroki Obayashi, Yanting Hou, Noriho Kamiya, Masahiro Goto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Japanese cedar pollinosis is a type I allergic disease and has already become a major public health problem in Japan. Conventional subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) cannot meet patients’ needs owing to the side effects caused by both the use of conventional whole antigen molecules in the pollen extract and the administration routes. To address these issues, a surface-modified antigen and transcutaneous administration route are introduced in this research. First, the pollen extract (PE) was conjugated to galactomannan (PE-GM) to mask immunoglobulin E (IgE)-binding epitopes in the PE to avoid side effects. Second, as a safer alternative to SCIT and SLIT, transcutaneous immunotherapy (TCIT) with a solid-in-oil (S/O) nanodispersion system carrying PE-GM was proposed. Hydrophilic PE-GM was efficiently delivered through mouse skin using S/O nanodispersions, reducing the antibody secretion and modifying the type 1 T helper (Th1)/ type 2 T helper (Th2) balance in the mouse model, thereby demonstrating the potential to alleviate Japanese cedar pollinosis.

Original languageEnglish
JournalPharmaceutics
Volume11
Issue number11
DOIs
Publication statusPublished - Nov 2019

Fingerprint

Seasonal Allergic Rhinitis
Pollen
Immunotherapy
Oils
Sublingual Immunotherapy
Cryptomeria
Cutaneous Administration
Surface Antigens
Masks
Immunoglobulin E
galactomannan
Epitopes
Japan
Public Health
Antigens
Skin
Antibodies
Research

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Transcutaneous delivery of immunomodulating pollen extract-galactomannan conjugate by solid-in-oil nanodispersions for pollinosis immunotherapy. / Kong, Qingliang; Higasijima, Kouki; Wakabayashi, Rie; Tahara, Yoshiro; Kitaoka, Momoko; Obayashi, Hiroki; Hou, Yanting; Kamiya, Noriho; Goto, Masahiro.

In: Pharmaceutics, Vol. 11, No. 11, 11.2019.

Research output: Contribution to journalArticle

Kong, Qingliang ; Higasijima, Kouki ; Wakabayashi, Rie ; Tahara, Yoshiro ; Kitaoka, Momoko ; Obayashi, Hiroki ; Hou, Yanting ; Kamiya, Noriho ; Goto, Masahiro. / Transcutaneous delivery of immunomodulating pollen extract-galactomannan conjugate by solid-in-oil nanodispersions for pollinosis immunotherapy. In: Pharmaceutics. 2019 ; Vol. 11, No. 11.
@article{996d82bdba84403c8ba0549d4bc03c12,
title = "Transcutaneous delivery of immunomodulating pollen extract-galactomannan conjugate by solid-in-oil nanodispersions for pollinosis immunotherapy",
abstract = "Japanese cedar pollinosis is a type I allergic disease and has already become a major public health problem in Japan. Conventional subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) cannot meet patients’ needs owing to the side effects caused by both the use of conventional whole antigen molecules in the pollen extract and the administration routes. To address these issues, a surface-modified antigen and transcutaneous administration route are introduced in this research. First, the pollen extract (PE) was conjugated to galactomannan (PE-GM) to mask immunoglobulin E (IgE)-binding epitopes in the PE to avoid side effects. Second, as a safer alternative to SCIT and SLIT, transcutaneous immunotherapy (TCIT) with a solid-in-oil (S/O) nanodispersion system carrying PE-GM was proposed. Hydrophilic PE-GM was efficiently delivered through mouse skin using S/O nanodispersions, reducing the antibody secretion and modifying the type 1 T helper (Th1)/ type 2 T helper (Th2) balance in the mouse model, thereby demonstrating the potential to alleviate Japanese cedar pollinosis.",
author = "Qingliang Kong and Kouki Higasijima and Rie Wakabayashi and Yoshiro Tahara and Momoko Kitaoka and Hiroki Obayashi and Yanting Hou and Noriho Kamiya and Masahiro Goto",
year = "2019",
month = "11",
doi = "10.3390/pharmaceutics11110563",
language = "English",
volume = "11",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Transcutaneous delivery of immunomodulating pollen extract-galactomannan conjugate by solid-in-oil nanodispersions for pollinosis immunotherapy

AU - Kong, Qingliang

AU - Higasijima, Kouki

AU - Wakabayashi, Rie

AU - Tahara, Yoshiro

AU - Kitaoka, Momoko

AU - Obayashi, Hiroki

AU - Hou, Yanting

AU - Kamiya, Noriho

AU - Goto, Masahiro

PY - 2019/11

Y1 - 2019/11

N2 - Japanese cedar pollinosis is a type I allergic disease and has already become a major public health problem in Japan. Conventional subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) cannot meet patients’ needs owing to the side effects caused by both the use of conventional whole antigen molecules in the pollen extract and the administration routes. To address these issues, a surface-modified antigen and transcutaneous administration route are introduced in this research. First, the pollen extract (PE) was conjugated to galactomannan (PE-GM) to mask immunoglobulin E (IgE)-binding epitopes in the PE to avoid side effects. Second, as a safer alternative to SCIT and SLIT, transcutaneous immunotherapy (TCIT) with a solid-in-oil (S/O) nanodispersion system carrying PE-GM was proposed. Hydrophilic PE-GM was efficiently delivered through mouse skin using S/O nanodispersions, reducing the antibody secretion and modifying the type 1 T helper (Th1)/ type 2 T helper (Th2) balance in the mouse model, thereby demonstrating the potential to alleviate Japanese cedar pollinosis.

AB - Japanese cedar pollinosis is a type I allergic disease and has already become a major public health problem in Japan. Conventional subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) cannot meet patients’ needs owing to the side effects caused by both the use of conventional whole antigen molecules in the pollen extract and the administration routes. To address these issues, a surface-modified antigen and transcutaneous administration route are introduced in this research. First, the pollen extract (PE) was conjugated to galactomannan (PE-GM) to mask immunoglobulin E (IgE)-binding epitopes in the PE to avoid side effects. Second, as a safer alternative to SCIT and SLIT, transcutaneous immunotherapy (TCIT) with a solid-in-oil (S/O) nanodispersion system carrying PE-GM was proposed. Hydrophilic PE-GM was efficiently delivered through mouse skin using S/O nanodispersions, reducing the antibody secretion and modifying the type 1 T helper (Th1)/ type 2 T helper (Th2) balance in the mouse model, thereby demonstrating the potential to alleviate Japanese cedar pollinosis.

UR - http://www.scopus.com/inward/record.url?scp=85075809844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075809844&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics11110563

DO - 10.3390/pharmaceutics11110563

M3 - Article

AN - SCOPUS:85075809844

VL - 11

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 11

ER -